Roth Capital Comments on BioRestorative Therapies, Inc.’s Q1 2024 Earnings (NASDAQ:BRTX)

BioRestorative Therapies, Inc. (NASDAQ:BRTXFree Report) – Equities research analysts at Roth Capital issued their Q1 2024 earnings per share (EPS) estimates for BioRestorative Therapies in a research report issued to clients and investors on Monday, February 12th. Roth Capital analyst J. Aschoff forecasts that the company will post earnings per share of ($0.52) for the quarter. The consensus estimate for BioRestorative Therapies’ current full-year earnings is ($3.52) per share. Roth Capital also issued estimates for BioRestorative Therapies’ Q2 2024 earnings at ($0.48) EPS, Q3 2024 earnings at ($0.53) EPS, Q4 2024 earnings at ($0.59) EPS, FY2027 earnings at $3.25 EPS and FY2028 earnings at $6.74 EPS.

BioRestorative Therapies Price Performance

BioRestorative Therapies stock opened at $1.45 on Tuesday. BioRestorative Therapies has a 52 week low of $1.20 and a 52 week high of $7.13. The business’s 50-day moving average price is $1.76.

BioRestorative Therapies (NASDAQ:BRTXGet Free Report) last released its earnings results on Monday, November 13th. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.04. BioRestorative Therapies had a negative return on equity of 117.00% and a negative net margin of 12,195.10%. The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. FNY Investment Advisers LLC acquired a new position in BioRestorative Therapies in the third quarter valued at approximately $26,000. Lynwood Capital Management Inc. acquired a new position in shares of BioRestorative Therapies during the 3rd quarter worth approximately $36,000. Finally, Vanguard Group Inc. raised its stake in shares of BioRestorative Therapies by 8.6% during the 3rd quarter. Vanguard Group Inc. now owns 137,818 shares of the company’s stock worth $247,000 after buying an additional 10,862 shares during the period. 6.93% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, major shareholder Dale Broadrick purchased 86,041 shares of the firm’s stock in a transaction on Friday, February 9th. The stock was bought at an average cost of $1.32 per share, with a total value of $113,574.12. Following the completion of the acquisition, the insider now owns 477,972 shares of the company’s stock, valued at approximately $630,923.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 21.60% of the company’s stock.

About BioRestorative Therapies

(Get Free Report)

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.

Further Reading

Receive News & Ratings for BioRestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioRestorative Therapies and related companies with MarketBeat.com's FREE daily email newsletter.